Sebastiaan De Schepper

Sebastiaan De Schepper

Auto-generated profile, based on publicly available information

Sebastiaan De Schepper

UK Dementia Research Institute, Institute of Neurology, University College London, London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Science
Verified
Journal Article
Closed access
TBTim Bartels
Tim Bartels
SSSebastiaan De Schepper
Sebastiaan De Schepper
SHSoyon Hong
Soyon Hong
Dementia is a rapidly rising global health crisis that silently disables families and ends lives and livelihoods around the world. To date, however, no early biomarkers or effective therapies exist. It is now clear that brain microglia are more than mere bystanders or amyloid phagocytes; they can act as governors of neuronal function and homeostasis in the adult brain. Here, we highlight the fundamental role of microglia as tissue-resident macrophages in neuronal health. Then, we suggest how chronic impairment in microglia-neuron cross-talk may secure the permanence of the failure of synaptic and neuronal function and health in Alzheimer’s and Parkinson’s diseases. Understanding how to assess and modulate microglia-neuron interactions critical for brain health will be key to developing effective therapies for dementia.

6 February 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
SSSebastiaan De Schepper
Sebastiaan De Schepper
JGJudy Z Ge
Judy Z Ge
GCGerard Crowley
Gerard Crowley
LFLaís Sousa da Silva Ferreira
Laís Sousa da Silva Ferreira
DGDylan Garceau
Dylan Garceau
SHSoyon Hong
Soyon Hong
Alzheimer’s disease (AD) is characterized by synaptic loss, which can result from dysfunctional microglial phagocytosis and complement activation. However, what signals drive aberrant microglia-mediated engulfment of synapses in AD is unclear. Here we report that secreted phosphoprotein 1 (SPP1/osteopontin) is upregulated predominantly by perivascular macrophages and, to a lesser extent, by perivascular fibroblasts. Perivascular SPP1 is required for microglia to engulf synapses and upregulate phagocytic markers including C1qa and Ctsb in presence of amyloid-β oligomers. Absence of Spp1 expression in AD mouse models results in prevention of synaptic loss. Furthermore, single-cell RNA sequencing and putative cell–cell interaction analyses reveal that perivascular SPP1 induces microglial phagocytic states in the hippocampus of a mouse model of AD. Altogether, we suggest a functional role for SPP1 in perivascular cells-to-microglia crosstalk, whereby SPP1 modulates microglia-mediated synaptic engulfment in mouse models of AD.

5 August 2020 in Developmental Neurobiology
Verified
Journal Article
Open access
PDF file
SSSebastiaan De Schepper
Sebastiaan De Schepper
GCGerard Crowley
Gerard Crowley
SHSoyon Hong
Soyon Hong
Genetic data implicate microglia as central players in brain health and disease, urging the need to better understand what microglia do in the brain. Microglia are critical partners in neuronal wiring and function during development and disease. Emerging literature suggests that microglia have diverse functional roles, raising the intriguing question of which functions of microglia become impaired in disease to undermine proper neuronal function. It is also becoming increasingly clear that microglia exist in heterogeneous cell states. Microglial cell states appear context‐dependent, i.e. , age, sex, location and health of their microenvironment; these are further influenced by external signaling factors including gut microbiota and lipid metabolites. These data altogether suggest that microglia exist in functional clusters that impact, and are impacted by, surrounding neuronal microenvironment. However, we still lack understanding of how we can translate microglia cell states into function. Here, we summarize the state‐of‐the‐art on microglial diverse functions in relation to neuronal health. Then we discuss heterogeneity during developing, healthy adult and diseased brains, and whether this may be pre‐determined by origin and/or regulated by local milieu. Finally, we propose that it is critical to gain high‐resolution functional discernment into microglia‐neuron interactions while preserving the spatial architecture of the tissue. Such insight will reveal specific targets for biomarker and therapeutic development toward microglia‐neuron crosstalk in disease.

28 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
SSSebastiaan De Schepper
Sebastiaan De Schepper
VKViktoras Konstantellos
Viktoras Konstantellos
JCJames A. Conway
James A. Conway
DSDimitra Sokolova
Dimitra Sokolova
LZLudovica Zaccagnini
Ludovica Zaccagnini
TBTim Bartels
Tim Bartels
Emerging evidence suggests that Parkinson’s disease (PD) may have its origin in the enteric nervous system (ENS), from where α-synuclein (αS) pathology spreads to the brain1,2,3,4. Decades before the onset of motor symptoms, patients with PD suffer from constipation and present with circulating T cells responsive to αS, suggesting that peripheral immune responses initiated in the ENS may be involved in the early stages of PD1,5,6,7. However, cellular mechanisms that trigger αS pathology in the ENS and its spread along the gut–brain axis remain elusive. Here we demonstrate that muscularis macrophages (ME-Macs), housekeepers of ENS integrity and intestinal homeostasis, modulate αS pathology and neurodegeneration in models of PD8,9. ME-Macs contain misfolded αS, adopt a signature reflecting endolysosomal dysfunction and modulate the expansion of T cells that travel from the ENS to the brain through the dura mater as αS pathology progresses. Directed ME-Mac depletion leads to reduced αS pathology in the ENS and central nervous system, prevents T cell expansion and mitigates neurodegeneration and motor dysfunction, suggesting a role for ME-Macs as early cellular initiators of αS pathology along the gut–brain axis. Understanding these mechanisms could pave the way for early-stage biomarkers in PD.

1 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
DSDimitra Sokolova
Dimitra Sokolova
SGShari Addington Ghansah
Shari Addington Ghansah
FPFrancesca Puletti
Francesca Puletti
TGTatiana Georgiades
Tatiana Georgiades
SSSebastiaan De Schepper
Sebastiaan De Schepper
SHSoyon Hong
Soyon Hong
Summary: Region-specific synapse loss is an early pathological hallmark in Alzheimer’s disease (AD). Emerging data in mice and humans highlight microglia, the brain-resident macrophages, as cellular mediators of synapse loss; however, the upstream modulators of microglia-synapse engulfment remain elusive. Here, we report a distinct subset of astrocytes, which are glial cells essential for maintaining synapse homeostasis, appearing in a region-specific manner with age and amyloidosis at onset of synapse loss. These astrocytes are distinguished by their peri-synaptic processes which are ‘bulbous’ in morphology, contain accumulated p62-immunoreactive bodies, and have reduced territorial domains, resulting in a decrease of astrocyte-synapse coverage. Using integrated in vitro and in vivo approaches, we show that astrocytes upregulate and secrete phagocytic modulator, milk fat globule-EGF factor 8 (MFG-E8), which is sufficient and necessary for promoting microglia-synapse engulfment in their local milieu. Finally, we show that knocking down Mfge8 specifically from astrocytes using a viral CRISPR-saCas9 system prevents microglia-synapse engulfment and ameliorates synapse loss in two independent amyloidosis mouse models of AD. Altogether, our findings highlight astrocyte-microglia crosstalk in determining synapse fate in amyloid models and nominate astrocytic MFGE8 as a potential target to ameliorate synapse loss during the earliest stages of AD.

9 July 2026 in Science
Verified
Journal Article
Closed access
GCGerard Crowley
Gerard Crowley
MKMinjung Kim
Minjung Kim
NONathanael O’NEill
Nathanael O’NEill
ETEmir Turkes
Emir Turkes
FGFateme Ghasemi
Fateme Ghasemi
SHSoyon Hong
Soyon Hong
Complement component 1q (C1q), the initiator of the classical complement cascade, mediates synaptic elimination in development and disease, yet the triggers for its deposition on synapses remain unclear. Using in vivo chemogenetics, we demonstrate that neuronal hyperactivity induces region-specific, C1q-dependent synapse loss in the adult hippocampus. Suppressing perforant pathway hyperactivity in a mouse model of Alzheimer’s disease reduced local amyloid-β amounts and C1q deposition and partially rescued synapse loss. Combining spatial transcriptomics, live cell tracking, and super-resolution microscopy, we identified association of antibody-secreting B-lineage cells in the adult hippocampus with activity-dependent, C1q-mediated synapse loss under physiological conditions. Together, these findings link neuronal hyperactivity to C1q-mediated synapse loss in the adult brain and implicate immunoglobulins as players in this process.